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a b s t r a c t
The phosphoinositide 3-kinase (PI3K)/AKT signalling pathway regulates many cellular functions including
proliferation, migration, survival and protein synthesis. Somatic mutations in PIK3CA, the gene encoding
the p110α catalytic subunit of PI3K enzyme, are commonly associated with many human cancers as well as
recently being implicated in human overgrowth syndromes. However, it is not clear if such mutations can
be inherited through the germline. We have used a novel mouse model with Cre recombinase (Cre)-
conditional knock-in of the common H1047R mutation into the endogenous Pik3ca gene. Heterozygous
expression of the Pik3caH1047R mutation in the developing mouse embryo resulted in failed ‘turning’ of the
embryo and disrupted vascular remodelling within the embryonic and extraembryonic tissues, leading to
lethality prior to E10. As vascular endothelial growth factor A (VEGF-A) signalling was disrupted in these
embryos, we used Cre under the control of the Tie2 promoter to target the Pik3caH1047R mutation
speciﬁcally to endothelial cells. In these embryos turning occurred normally but the vascular remodelling
defects and embryonic lethality remained, likely as a result of endothelial hyperproliferation. Our results
conﬁrm the lethality associated with heterozygous expression of the Pik3caH1047R mutation during
development and likely explain the lack of inherited germline PIK3CA mutations in humans.
& 2015 Elsevier Inc. All rights reserved.
Introduction
The phosphoinositide 3-kinase (PI3K)/AKT signalling pathway
regulates processes critical for cell proliferation, growth, migration,
survival and angiogenesis (Vanhaesebroeck et al., 2012). The p110α
catalytic subunit of class 1A PI3Ks is encoded by the gene PIK3CA.
Somatic mutations within this gene are commonly observed in many
human cancers including breast and colon cancers (Samuels and
Waldman, 2010; Zardavas et al., 2014). The majority of PIK3CA
mutations cluster at three hot spots within the protein, two in the
helical domain (E542 and E545) and one in the kinase domain
(H1047), and cause the constitutive activation of the PI3K/Akt
signalling pathway (reviewed in Chalhoub and Baker (2009)). Inter-
estingly, similar mutations, including the common cancer-associated
‘hot spot’ mutations, have also recently been observed in overgrowth
conditions such as megalencephaly syndromes (Lee et al., 2012;
Riviere et al., 2012), ﬁbroadipose hyperplasia (Lindhurst et al., 2012)
and Congenital Lipomatous Overgrowth with Vascular, Epidermal, and
Skeletal anomalies (CLOVES) (Kurek et al., 2012).
Cancer-associated PIK3CA mutations are invariably somatic and
PIK3CA-driven overgrowth syndromes are not inherited suggest-
ing that PIK3CA mutations are not compatible with germline
transmission. Consistent with this, germline homozygous loss of
phosphatase and tensin homologue (Pten), a negative regulator of
PI3K, during murine development is fatal before embryonic day (E)
11.5 due to vascular abnormalities resulting in bleeding and
cardiac failure that arise from aberrant endothelial cell (EC)
proliferation (Hamada et al., 2005).
Interestingly, mice lacking the p110α subunit (Bi et al., 1999;
Lelievre et al., 2005), or expressing a kinase-dead version of the
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p110α isoform (Graupera et al., 2008), are also embryonic lethal,
albeit at slightly varying stages of mid-gestation. Notably, in both
cases embryonic lethality is suggested to arise from impaired EC
development in which cell migration, proliferation and survival
are variably affected. Mice expressing the kinase-dead p110α
speciﬁcally in ECs demonstrated similar migration and motility
defects with lethality occurring before E12.5 (Graupera et al.,
2008). Similarly, the combined ablation of both Akt1 and Akt3
results in embryonic lethality at approximately E11 caused by a
decreased vasculature and other cardiovascular defects as well as
increased apoptosis in the developing nervous system (Yang et al.,
2005). However, Akt1þ /Akt2/Akt3/ embryos are able to
survive embryogenesis (Dummler et al., 2006) suggesting that
Akt1, in particular, is essential for embryogenic development.
These mouse models indicate that tight regulation of PI3K/AKT
pathway activity is essential during embryonic development
suggesting that mutations which disrupt the normal physiological
activity of PIK3CA would be unlikely to be heritable. Nevertheless,
germline transmission of PIK3CA mutations has recently been
reported in 8 individuals with Cowden or “Cowden-like” syn-
drome (Orloff Mohammed et al., 2013). However, the reported
mutations are not within known oncogenic ‘hot spot’ regions in
the PIK3CA gene.
In order to determine if the cancer-causing PIK3CA ‘hot spot’
mutations can indeed be transmitted through the germline, we
have used a mouse model with a Cre recombinase (Cre)-condi-
tional knock-in of the common cancer-associated H1047R muta-
tion into the endogenous Pik3ca gene (Kinross et al., 2012; Tikoo
et al., 2012; Hare et al., 2014). We show that both ubiquitous and
EC-speciﬁc expression of the Pik3caH1047R mutation during
embryonic development lead to severe vascular malformations
that result in lethality prior to E10.5.
Materials and methods
Generation of mice
Pik3caLat-H1047R mice, generated as previously described (Kinross
et al., 2012), were mated to either Cre-deleter (B6.C-Tg(CMV-cre)
1Cgn/J) transgenic mice which ubiquitously express Cre recombinase
(Cre) from the zygote stage of development (Schwenk et al., 1995) or
Tie2Cre (B6.Cg-Tg(Tek-cre)1Ywa/J) transgenic mice whose Cre
expression is under the control of the EC-speciﬁc Tie2 promoter
(Kisanuki et al., 2001). All mice strains were maintained on the
C57BL/6 background. For crosses involving the Cre-deleter strain,
female Cre-deleterþ / mice were crossed with male Pik3caLat-H1047R/
WT mice. The RosaLacZ (B6;129S4-Gt(ROSA)26Sortm1Sor/J) transgenic
reporter mouse strain (Soriano, 1999) was used for veriﬁcation of
Cre-mediated recombination in both the Cre-deleter and Tie2Cre
embryos.
Offspring heterozygous for either Cre-deleter (Cre-del), Tie2Cre
(Tie2Cre) or Pik3caH1047R alone (Pik3ca) were classiﬁed as controls
while those heterozygous for both Cre-deleter and Pik3caH1047R
(Cre-del:Pik3ca) or Tie2Cre and Pik3caH1047R (Tie2Cre:Pik3ca) were
classiﬁed as mutants.
All experimental procedures involving animals were approved
by the Peter MacCallum Cancer Centre Animal Experimentation
Ethics Committee and conducted in accordance with the National
Health and Medical Research Council (NHMRC) Australian Code of
Practise for the Care and Use of Animals for Scientiﬁc Purposes.
Embryo collection
Blastocysts were collected at E3.5 as previously described
(Nagy et al., 2003a). Brieﬂy, Cre-del female mice were injected
with 5 i.u. of pregnant mare's serum gonadotropin (PMS: Folligon,
Intervet) followed by 2.5 i.u. of human chorionic gonadotropin
(hCG: Chorulon, Intervet) 48 h later, to stimulate ovulation. This
was followed by overnight mating with a male Pik3caLat-H1047R/WT
mouse. Two days later, pregnant females were culled and E2.5
morula collected and placed in culture overnight at 6% CO2 in
Cooks blastocyst media (Cook Medical, Australia) before DNA was
extracted from individual E3.5 embryos for genotyping.
Embryos were obtained from timed matings with the day of
the detection of a vaginal plug considered as E0.5. Embryos and
yolk sacs between E8.5 and E14.5 were isolated as previously
described (Nagy et al., 2003b). Yolk sacs were taken for DNA
isolation and genotyping when possible. Alternatively, when yolk
sacs were required, embryo tails were used for genotyping.
PCR genotyping of embryos
Embryo tails or yolk sacs were placed in cell lysis buffer
consisting of 50 mM Tris pH 8.8, 10 mM (NH4)SO4, 6.5 mM MgCl2,
0.5% Triton X-100 and 1% β-mercaptoethanol (200 μL for E10–14.5,
100 μL for E8–9.5 and 20 μL for E3.5 embryos) and proteinase-K
added to a ﬁnal concentration of 150 μg/mL. Following overnight
incubation at 55 1C, samples were heated to 95 1C for 15 min,
mixed well and centrifuged at 13,000 rpm for 5 min. The primers
for analysis of Cre and Pik3ca genotypes, and PCR conditions for
each reaction, were as previously described (Kinross et al., 2012).
Immunoﬂuorescence and LacZ staining
Freshly isolated embryos and yolk sacs were ﬁxed in cold 4%
paraformaldehyde at 4 1C for 2 h. For immunolabelling, cryosec-
tions or wholemount embryos were blocked in 10% (v/v) goat
serum, 0.2% (w/v) BSA, 0.2% (v/v) Triton X-100 in phosphate-
buffered saline (PBS), and stained with the indicated primary
antibodies overnight at 4 1C. Antibodies used included: rabbit
anti-cleaved caspase 3 (Cell Signalling Technology, Danvers, MA)
1:500; rabbit anti-phospho-Histone H3 (Cell Signalling Technol-
ogy) 1:500; rat anti-endomucin (Santa Cruz, Dallas, TX) 1:50; goat
anti-Nrp1 (R&D, Minneapolis, MN) 1:500; rabbit anti-Nrp2 (Cell
Signalling Technology) 1:500; rat anti-PECAM/CD31 (Biolegend,
San Diego, CA) 1:200; goat anti-VEGFR (R&D, Minneapolis, MN)
1:200; mouse anti-smooth muscle actin (Sigma) 1:500. Cyrosec-
tions and cells were mounted in Prolong Gold antifade reagent
with DAPI (Molecular Probes, Mulgrave, Australia). Confocal
images were acquired on a LSM 700 (Zeiss) system.
For LacZ staining, embryos were ﬁxed in cold PBS containing 2%
(v/v) formalin and 0.2% (v/v) gluteraldehyde for 2 h at 4 1C. Embryos
were then rinsed in PBS before being immersed in staining solution
(5 mM potassium ferrocyanide, 5 mM potassium ferricyanide,
2 mM MgCl2 and 1 mg/mL X-Gal in PBS) for 6–12 h at 37 1C.
RNA isolation and RT-PCR
RNA was extracted from E9.5 embryos using an RNeasy Mini kit
(Qiagen) and reverse transcribed using the Transcriptor First Strand
cDNA Synthesis kit (Roche). The QuantiTect Primer Assays (Qiagen) were
used in combination with the QuantiTect SYBR Green RT-PCR kit
(Qiagen) for analysis of the expression of various vascular growth factors
(VGFs). Qiagen Quantitect primers used included EphrinB2 (cat.
#QT00139202), Tgfβ (cat. #QT00135828), Vegf-A (cat. #QT00160769),
Vegf-C (cat. #QT00104027), Vegfr1 (Flt1 – cat. #QT00096292), Vegfr2 (Flk1
– cat. #QT00097020), Vegfr3 (Flt4 – cat. #QT00099064), Ang1 (cat.
#QT00143381), Ang2 (cat. #QT00326256), Nrp1 (cat. #QT00157381) and
Nrp2 (cat. #QT00154427). Primers were designed for Foxo1 (sense 5′-
TGTCAGGCTAAGAGTTAGTGAGCA-3′ and antisense 5′-GGGTGAAGGGG-
CATCTTTG-3′) and Foxo3a (sense 5′-AGCAGGCCTCATCAAAG-3′ and
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antisense 5′-CGTCAGTTTGAGGGTCTGC-3′) from Integrated DNA Tech-
nologies (IDT, Baulkham Hills, Australia).
Results
Ubiquitous expression of the heterozygous Pik3caH1047R mutation is
embryonically lethal by E10.5
We have used the Cre-deleter mouse strain, which expresses
Cre in all cells of the developing mouse embryo (veriﬁed by
crossing this line with the R26RLacZ reporter mouse strain
(Supplementary Fig. 1)), and the Cre-conditional Pik3caH1047R
knock-in mouse strain (Pik3caLat-H1047R) (Kinross et al., 2012;
Tikoo et al., 2012) to ubiquitously express the Pik3caH1047R muta-
tion during embryogenesis. When the Cre-deleter mouse was
crossed to the Pik3caLat-H1047R mouse no Cre-deleterþ /:Pik3-
caH1047R/WT (Cre-del:Pik3caH1047R) mutant pups were observed
(p¼0.0002, Table 1).
Timed matings were performed to establish the stage at which
the Pik3caH1047R mutation was causing lethality. A total of 250
embryos between E8.5 and E9.5 were genotyped, 68 (27%) of
which were Cre-del:Pik3caH1047R, as expected for normal Mende-
lian inheritance. However, genotyping of embryos between E10.5
and 14.5, identiﬁed the Cre-del:Pik3caH1047R genotype only in
resorbed embryos demonstrating Cre-del:Pik3caH1047R mutant
embryos are not viable past developmental day E9.5 (Table 2).
At E8.5, mutant embryos were indistinguishable to controls
with similar numbers of somites and overall size (Fig. 1A). Strik-
ingly, compared to littermate controls (Fig. 1A–F), E9.5 Cre-del:
Pik3caH1047R mutant embryos were signiﬁcantly smaller, paler in
colour, and had not completed the critical turning process into the
fetal position (Fig. 1G–I). At this stage mutant embryos had
truncation of the posterior trunks, pronounced deﬁciency of the
craniofacial primordia, failure of neural tube closure, and a
number of absent somites. Mutant embryos were observed to
have rhythmic heart beats consistent with myocardial contrac-
tions. However, blood ﬂow, detected by erythrocyte movement in
the heart and other regions of the body, was diminished in mutant
embryos. Consistent with this observation, when the embryos
were sectioned and eosin stained, blood cells were identiﬁed in
mutants but were reduced in comparison to controls (Q.S., L.H. and
S.W., data not shown) suggesting blood development may be
compromised in the mutant embryo's. Importantly, the mutant
embryos demonstrated increased activity of the PI3K/AKT path-
way as evidenced by increased levels of pAkt compared to wild
type control embryos (Supplementary Fig. 2).
Cardiovascular and angiogenic defects are observed in Cre-deleter:
Pik3caH1047R embryos
The onset of blood ﬂow through the cardiovascular system at
E8.5–10 is a critical developmental event to provide oxygen and
nutrients to the growing embryo. As this is the time at which
embryonic lethality is observed in the Cre-del:Pik3caH1047R hetero-
zygous mutant mice, we investigated if aberrant blood vessel
formation within the embryo may be a potential cause of embryo-
nic death. Whole mount endomucin staining, a marker of endothe-
lial cells, was performed to visualise the vasculature. At E9.5,
control embryos displayed a highly ordered vasculature consisting
of a complex network of arteries and veins that branch throughout
the embryo (Fig. 2A). Endomucin staining revealed that mesoder-
mal precursors have differentiated into endothelial cells and
further condensed into a primitive vascular network in mutant
embryos with presence of the major vessels including the dorsal
aorta and anterior cardinal veins. However, in comparison to
control embryos, their vasculature was severely disorganised and
incomplete with a lack of remodelling of the primitive vascular
plexus into more complex structures (Fig. 2A). This was particu-
larly evident in the cranial and intersomitic vessels of these
embryos with no clear distinction between large and small vessels
with an incomplete network in some areas (indicated by white
arrow and arrowhead, respectively, Fig. 2A).
Transverse sections through the 3rd pharyngeal arch clearly
demonstrate aberrant formation of the major vessels, including the
dorsal aorta, anterior cardinal vein and pharyngeal arch arteries in
Cre-del:Pik3caH1047R mutant embryos (Fig. 2B and C). Where in
controls endomucin positive endothelial cells are highly ordered
and line vessels with a large lumen, the Cre-del:Pik3caH1047R mutants
lack this organised structure with only a small number of endothe-
lial cells and signiﬁcantly reduced lumen size consistent with
reduced blood ﬂow (Fig. 2B and C).
Remodelling of the primitive vascular network into a higher
order complex of arteries, veins and arterioles is an essential
process for the correct function of the cardiovascular system, and
is thought to be dependant, in part, on haemodynamic forces
produced by blood ﬂow (Garcia and Larina, 2014). As Cre-del:
Pik3caH1047R mutants had pronounced angiogenic defects and
were deﬁcient in blood ﬂow we next asked if the major vessels
had become speciﬁed. Using antibodies to Nrp1 and Nrp2 that
preferentially label either arteries or veins, respectively, we found
that vessels failed to remodel in mutant embryos. Thus, in
comparison to controls, Nrp1 did not label arterial vessels of the
dorsal aorta or the pharyngeal arch arteries (inset and marked by
Δ respectively in Fig. 2B), and Nrp2 did not label the anterior
cardinal vein in the mutant embryos (inset, Fig. 2C).
Extraembryonic vessel remodelling defects observed as a result of
mutant Pik3caH1047R expression
Previous work has suggested that defects in vessel formation (or
function) and blood formation in extraembryonic tissues may cause
death in developing embryos. In comparison to control embryos,
the yolk sacs from E9.5 Cre-del:Pik3caH1047R embryos were pale,
wrinkled, lacked visible blood-ﬁlled vitelline vessels (Fig. 3A), and
possessed endothelial lined ‘lacunae’ (white arrows, Fig. 3B).
Staining of whole yolk sacs with vascular markers such as VEGFR2
and CD31 clearly demonstrate the complex network of vessels formed
in the controls (top panel, Fig. 3C and Supplementary Fig. 3). In
contrast, mutant yolk sacs lacked remodelling of the vasculature into a
complex ordered network with rare regions of avascular space (white
arrows, lower panel, Fig. 3C and Supplementary Fig. 3). We next
analysed proliferation and apoptosis in E9.5 Cre-del:Pik3caH1047R yolk
sacs using antibodies to phosphorylated histone H3 (PHH3) and
activated caspase 3, respectively. Although no notable differences in
apoptosis were identiﬁed, a striking increase in proliferating cells in
Cre-del:Pik3caH1047R yolk sacs was observed, consistent with previous
reports showing that the Pik3caH1047R mutation leads to constitutive
Table 1
Genotype percentages expected and numbers observed when heterozygous Cre-
deleter mice were crossed with heterozygous Pik3caH1047R mice.
Genotypes
Expected N (%) Actuala N (%)
Cre-deleter Cre-deleterþ Cre-deleter Cre-deleterþ
Pik3caWT 15 (25) 15 (25) 21 (35) 20 (30)
Pik3caH1047R 15 (25) 15 (25) 19 (25) 0 (0)b
a Results from 9 litters (60 pups).
b p¼0.0002 (χ2 test).
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PI3K activation and proliferation (Isakoff et al., 2005; Layton et al.,
2012; Samuels et al., 2005). Transverse sections of the yolk sacs further
conﬁrmed the lack of vascular remodelling with dramatically
increased space between the extraembryonic endoderm and meso-
derm in the mutants compared to controls (Fig. 3D). Microscopic
analysis also conﬁrmed fewer blood cells (indicated by arrowheads)
within the mutant yolk sacs (Fig. 3D).
We next assessed embryos at E8.5. Early vessel formation
within both control and mutant embryos progressed normally
with obvious formation of the paired dorsal aorta (Fig. 4A). In
contrast, striking defects were evident in the yolk sacs of E8.5 Cre-
del:Pik3caH1047R mutant animals suggesting the angiogenic defects
progress from the onset of vessel formation. Mutant yolk sacs
lacked remodelling of the primitive vascular plexus with absence
of an ordered network. Consistent with the analysis at E9.5, the
E8.5 Pik3caH1047R mutant yolk sacs also demonstrated a clear
increase in the number of proliferating cells compared to controls
(arrowheads, Fig. 4A). Staining of yolk sac sections with VEGFR2
and eosin clearly shows blood islands have formed in the Cre-del:
Pik3caH1047R yolk sacs but with fewer blood cells present and
vacuole space much larger than controls (indicated by black and
white bars, Fig. 4B).
Taken together, these ﬁndings show that mesodermal precur-
sors have differentiated into endothelial cells and condensed into a
Fig. 1. Ubiquitous embryonic expression of the Pik3caH1047R mutation leads to disrupted morphology from E8.5 and no survival past E9.5. Mouse embryos from the Cre-
deleterþ / (Cre-del)xPik3caH1047R/WT (Pik3caH1047R) cross were dissected at several different time points during development; E8.5 (A–C), E9.0 (D–F) and E9.5 (G–I). Mutant
embryos were those heterozygous for both Cre-del and the Pik3caH1047R mutation (Cre-del:Pik3caH1047R) while Cre-del alone and Pik3caH1047R alone are littermate control
embryos. Scale bars, 500 μm.
Table 2
Genotypes of embryos from the Cre-deleterþ /xPik3caH1047R/WT crosses observed at various developmental time points during mouse embryogenesis.
Embryonic age Genotype N Total N Resorbed embryosa N Probability (χ2 test)
Cre-delþ:Pik3caH1047R Cre-delþ:Pik3caWT Cre-del:Pik3caH1047R Cre-del:Pik3caWT
3.5 10 5 6 5 26 – NSb
8.5 27 32 21 27 107 0 NS
9.0 11 8 6 2 27 2 NS
9.5 30c 33 25 28 116 1 NS
10.5 2d 12 8 6 28 7 (4e) po0.05
11.5 0 12 15 10 37 10 (1e) po0.001
12.5 0 12 16 5 33 4 (3e) po0.001
14.5 0 2 8 6 16 6 po0.05
Total 80 117 105 89 390 27
a Resorbed embryos could not be genotyped.
b NS, not signiﬁcant.
c All Creþ:Pik3caH1047R embryos observed at E9.5 showed visible changes in morphology as they were smaller in size and were not fully turned.
d Two Creþ:Pik3caH1047R embryos were found at E10.5 but were clearly not viable.
e Sufﬁcient tissue was collected from these resorbed embryos to conduct genotyping and were conﬁrmed to be Cre-delþ :Pik3caH1047R.
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Fig. 2. Ubiquitous germline expression of the Pik3caH1047R mutation leads to severe defects in vascular remodelling and angiogenesis in the developing embryo.
(A) Representative whole-mount images are shown of control (Cre-del) and mutant (Cre-del:Pik3caH1047R) embryos at E9.5 stained with the endothelial cell marker
endomucin (green). Reduced vascular networking in the head (white arrowhead) and the intersomitic region (ISV) are indicated on mutant embryos. Transverse sections
through the pharyngeal arch territory of E9.5 Cre-del control and Cre-del:Pik3caH1047R embryos were stained for endomucin (green) and either Nrp1 (B) or Nrp2 (C) in red
with all sections counterstained for DAPI (blue). Nrp1 staining was absent in the DA of mutant embryos (inset, B) while Nrp2 staining is absent in the ACV of mutant embryos
(inset, C). Anatomical features are indicated with the following abbreviations-ACV, anterior cardinal vein; DA, dorsal aorta; e, eye; nt, neural tube; ov, otic vesicle; PAA,
pharyngeal arch artery. Scale bars 100 mm.
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primitive vascular network in mutant embryos, but that the
process of angiogenesis and vascular remodelling is compromised.
Our data further suggest that the major vascular defects occur
during vessel remodelling which in turn leads to compromised
blood ﬂow and embryonic death.
Constitutive PI3K/Akt signalling by the Pik3caH1047R mutation affects
VEGF expression
Development of the vasculature is heavily dependent on
vascular endothelial growth factor A (VEGF-A) signalling
(reviewed in Olsson et al. (2006)). As PI3K acts as a positive
effector of VEGF levels, we proﬁled the mRNA expression of
important members of the VEGF signalling pathway in E9.5 Cre-
del:Pik3caH1047R embryos and yolk sacs by RT-PCR (Fig. 5). Expres-
sion of Vegf-A, Vegfr2 and Nrp2 were signiﬁcantly increased in the
Cre-del:Pik3caH1047R mutant embryonic tissues (Fig. 5A, D and J). In
contrast, only Nrp1 was signiﬁcantly increased in the yolk sacs of
Cre-del:Pik3caH1047R mutants (Fig. 5K). There was also a general
trend for all assessed VEGF signalling factors to be up-regulated in
the Pik3caH1047R mutant tissues suggesting constitutive PI3K/Akt
signalling as a result of the Pik3caH1047R mutation increases activity
of the VEGF pathway during early development of both the intra
and extraembryonic tissues.
While PI3K activation has been demonstrated to block the
function of Foxo proteins (Martinez-Gac et al., 2004), we found
that Cre-del:Pik3caH1047R mutants showed increased expression of
both Foxo1 and Foxo3a in the embryo and, to a lesser extent, in the
yolk sac (Fig. 5L and M), which is possibly contributing to the
vessel remodelling and maturation defects.
Expression of the Pik3caH1047R mutation in endothelial cells causes
lethality by E11.5
As the ubiquitously expressed Pik3caH1047R mutation had pro-
nounced effects on vessel development, we sought to determine if
this was under the control of cell autonomous changes in endothelial
cells. To speciﬁcally target the mutation to endothelial cells we
crossed Pik3caLat-H1047R mice to the Tie2Cremouse strain inwhich Cre
expression is restricted to the developing vascular system
(Supplementary Fig. 1). No Tie2Creþ /:Pik3caH1047R/WT (Tie2Cre:Pik3-
caH1047R) pups were born and analysis of embryos at various time
points revealed lethality was occurring prior to E11.5 (Table 3).
Morphological analysis at E9.5 showed that, unlike the Cre-del:
Pik3caH1047R embryos, Tie2Cre:Pik3caH1047R embryos had undergone
the turning process and had normal patterning of the anterior–
posterior axis, although overall growth was retarded (Fig. 6A).
At E10.5, Tie2Cre:Pik3caH1047R mutant embryos were signiﬁcantly
smaller and developmentally delayed compared to wild type litter-
mates and were comparable in size to mutant embryos at E9.5
(Fig. 6A). While E9.5 Tie2Cre:Pik3caH1047R mutant embryos were
observed to have a heartbeat, few E10.5 mutant embryos displayed
a heartbeat and, in those that did, the contractions were signiﬁcantly
slower and less frequent. Together, this suggests that the mutant
Fig. 3. Extraembryonic defects were observed at E9.5 after ubiquitous expression got the Pik3caH1047R mutation. (A) Gross morphology images of the yolk sacs surrounding
the embryos of Cre-del control and Cre-del:Pik3caH1047R mutants. Scale bars, 500 mm. (B) Bright ﬁeld images of E9.5 yolk sacs demonstrate endothelial lined ‘lacunae’ in the
mutant yolk sacs (indicated by white arrows). (C) Wholemount staining of yolk sacs from Cre-del control and Cre-del:Pik3caH1047R mutant embryos at E9.5 was performed
with anti-VEGFR2 antibodies (red). Higher magniﬁcation images are shown inset with lacunae indicated by white arrows. (D) Serial yolk sac sections were stained for
VEGFR2 (red) and DAPI (blue, left panels) and eosin (right panels). Arrowheads indicate blood cells within blood vessels in both control and mutants. bv, blood vessel; en,
endoderm; me, mesoderm. Scale bars for B, C and D, 100 mm.
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embryos had stopped developing and tissue autolysis had begun at
E10.5. Blood ﬂow was deﬁcient in mutant embryos at E9.5, while at
E10.5 both the mutant yolk sac and embryo had reduced blood
accumulations suggesting that primitive haematopoiesis is affected
by the Pik3caH1047R mutation.
Cardiac and vascular defects observed in Tie2Cre speciﬁc Pik3caH1047R
embryos
Endomucin staining of Tie2Cre:Pik3caH1047R embryos demon-
strated a disorganised and truncated vascular network (Fig. 6B)
similar to that observed in the Cre-del:Pik3caH1047R embryos
(Fig. 2A). At E9.5, whole mount endomucin staining revealed
Tie2Cre:Pik3caH1047R mutant embryos have formed the major
vessel branches of the dorsal aorta and anterior cardinal veins
but had failed to undergo vessel remodelling and sprouting in the
head (arrows), somites, dorsal regions of the embryo, and into the
pharyngeal arches (Fig. 6B).
Transverse sections through the pharyngeal arch territory were
stained for endomucin. While the dorsal aorta and anterior
cardinal vein could be detected in all mutants there was an overall
decrease in vascular density in the Tie2Cre:Pik3caH1047R embryos
compared to controls (Fig. 7A and B). At E9.5, arterial and venous
speciﬁcation was also absent in Tie2Cre:Pik3caH1047R embryos
(Fig. 7A). Thus, similar to Cre-del:Pik3caH1047R mutants, Nrp1 and
Nrp2 staining was absent in the dorsal aorta and anterior cardinal
vein of Tie2Cre:Pik3caH1047R embryos (Fig. 7A and B ).
Vascular defects were also observed in the extraembryonic
tissues of Tie2Cre:Pik3caH1047R mutants. Morphological analysis of
whole yolk sacs at E9.5 and E10.5 showed defects similar to those of
the Cre-del:Pik3caH1047R mutants. The yolk sacs from Tie2Cre:Pik3-
caH1047R embryos appear wrinkled and have disrupted vascular
development compared to Tie2Cre controls (Fig. 8A and
Supplementary Fig. 4A). Large vitelline vessels are observed in the
control yolk sacs at E9.5 and E10.5, however, these are absent in the
mutant yolk sacs with the presence of small blood patches which are
not organised into a vascular network and distinct vessel lined
‘lacunae’ (Fig. 8A and Supplementary Fig. 4A). VEGFR2 staining of
whole yolk sacs revealed vessel remodelling defects in mutants
where the vasculature failed to form a complex network with rare
regions of avascular space (Fig. 8B). Further analysis of E9.5 yolk sacs
demonstrates increased proliferation (Supplementary Fig. 5A) with
no changes in levels of apoptosis (Supplementary Fig. 5B). As such,
endothelial cells appear to be hyperproliferating as a result of
Fig. 4. Extraembryonic defects caused by the Pik3caH1047R are evident at E8.5. (A) Wholemount staining of E8.5 yolk sacs and embryos with anti-VEGFR2 antibodies (red) and
anti-PHH3 antibodies (blue) are shown for a control (Cre-del) and mutant (Cre-del:Pik3caH1047R). Higher magniﬁcation of vessels are shown inset. Arrows point to regions in
which there is a lack of remodelling in the mutant. Arrowheads indicate PHH3 positive cells in the Cre-del:Pik3caH1047R mutant embryo and yolk sac. DA, dorsal aorta. Scale
bars 100 mm. (B) Serial sections through the yolk sac were stained for VEGFR2 (red) and DAPI (blue, top panel) or eosin (bottom panel). White and black close ended bars
indicate the increased length of vacuole space in the Cre-del:Pik3caH1047R mutant yolk sacs. bi, blood island; en, endoderm; me, mesoderm. Scale bars 50 mm.
L.M. Hare et al. / Developmental Biology 404 (2015) 14–2620
Fig. 5. Expression of genes involved in vascular development are deregulated in Cre-del:Pik3caH1047R embryos and yolk sacs. Real-time PCR analysis of various vascular
growth factor genes were assessed in control (Cre-del) and H1047R mutant (Cre-del:Pik3caH1047R) embryos and yolk sacs. The expression values obtained from the mutant
embryos and yolk sacs were normalised to the expression values of control embryos and yolk sacs respectively. All samples were normalised to the housekeeping gene β-
actin which was expressed at equivalent levels in all samples. Each data point represents an individual embryo or yolk sac with results represented as the mean7SEM.
Statistical differences were determined using the Student's t-test.
L.M. Hare et al. / Developmental Biology 404 (2015) 14–26 21
constitutive PI3K signalling but are unable to remodel and form the
necessary cell–cell connections to form vessels. Transverse sections
of VEGFR2 stained Tie2Cre:Pik3caH1047R yolk sacs conﬁrmed the
vessel remodelling defect with signiﬁcantly increased space between
the extraembryonic endoderm and mesoderm in mutants compared
to controls (left panel, Fig. 8C). Eosin staining of yolk sac sections
clearly demonstrates fewer blood cells in the Tie2Cre:Pik3caH1047R
mutants with a lack of distinct blood islands and widening of the
blood vessels (right panel, Fig. 8C).
By E10.5, there are very few endothelial cells remaining in the
Tie2Cre:Pik3caH1047R mutant yolk sacs with a striking lack of any
discernible vasculature (Supplementary Fig. 4A). Notably, the few
remaining CD31 positive cells were separated from each other
(Supplementary Fig. 4A) or had formed stunted blood ﬁlled tubes.
Counterstaining of E10.5 yolk sacs with alpha-smooth muscle actin
demonstrates that some of the stunted vascular tubes are aligned
by smooth muscle and have adopted an arterial-like phenotype
(Supplementary Fig. 4B).
Discussion
We have used a novel mouse model with a Cre-conditional
heterozygous knock-in of the Pik3caH1047R mutation to examine
the consequences of germline transmission of this genetic defect.
As the mutation is knocked into the endogenous gene, expression
is under the control of the endogenous Pik3ca promoter and thus
the mutant protein is only expressed by cells that normally express
Pik3ca and at normal physiological levels.
Using the Cre-deleter model to induce ubiquitous expression of
the mutation from the earliest stages of embryogenesis we demon-
strate that the Pik3caH1047R mutation is lethal by E10.5. This lethality
likely occurs at multiple levels. Restricting the expression of the
mutation speciﬁcally to ECs using the Tie2-Cre model resulted in
severe vascular defects and embryonic death. However, in this case,
death occurred a day later (at E11.5) and the embryos did not
demonstrate the turning defect noted in the embryos that ubiqui-
tously expressed Pik3caH1047R. This suggests that ubiquitous expres-
sion of Pik3caH1047R results in other potentially lethal events in
addition to its effects on vascular development.
Pik3caH1047R, and related cancer-associated Pik3ca mutations,
result in increased speciﬁc activity of p110α catalytic subunit of
PI3K and up-regulation of the PI3K/AKT pathway (Isakoff et al., 2005;
Layton et al., 2012; Samuels et al., 2005). Our results are thus
consistent with previous studies in which the PI3K/AKT pathway
was up-regulated by homozygous deletion of Pten, a negative
regulator of this pathway. No Pten/ embryos are observed beyond
E7.5 (Hamada et al., 2005; Di Cristofano et al., 1998), while removal
of Pten in endothelial cells resulted in embryonic lethality before
E11.5 due to bleeding and cardiac failure caused by the failure of
vessels to recruit mural cells to support the vascular wall (Hamada
et al., 2005). Interestingly, both ubiquitous knockout of Pik3ca
(Lelievre et al., 2005) and ubiquitous or EC-speciﬁc expression of a
kinase-dead Pik3ca allele (Graupera et al., 2008) have also been
reported to cause embryonic lethality at mid-gestation due to severe
vascular defects. Taken together with our own data, these ﬁndings
demonstrate that while p110α, the protein product of the Pik3ca
gene, is essential for embryogenesis, tight control of its activity is
vital for normal embryonic development.
Development of the blood vasculature system during embry-
ogenesis involves a complex and intricate series of biological
processes that rely on controlled expression of many signalling
pathways, including the VEGF and PI3K/AKT pathways. Here we
demonstrate that ubiquitous and EC-targeted expression of the
Pik3caH1047R mutation causes dramatic embryonic and extraem-
bryonic vascular defects. Whereas the formation of vessels from
mesodermal precursors (vasculogenesis) was clearly observed in
mutant embryos and yolk sacs, the primitive vasculature failed to
remodel resulting in embryonic lethality. The dramatic vascular
remodelling defects and enlargement of vessels observed in the
yolk sacs of both the ubiquitous and EC speciﬁc mutants at E9.5
provide a likely explanation to the reduced haemodynamic force
within the embryo that in turn leads to embryonic vascular defects
and embryonic lethality. Our data further ﬁt with the notion that
the vascular defects arise as a result of aberrant proliferation, a
ﬁnding that is in agreement with previous studies investigating
oncogenic PI3K mutations in vivo (Kinross et al., 2012; Tikoo et al.,
2012). In addition to EC hyperproliferation, our data also suggest
that VEGF-mediated hyperfusion may also play a role in the
development of enlarged vessels in the yolk sacs of Pik3caH1047R
mutants. Indeed, mice over expressing VEGF to a similar degree as
reported here have similar vessel defects in the yolk sacs that result
from aberrant fusion of the primitive blood vessels (Drake and
Little, 1995; Takahashi et al., 2003).
VEGF-A was originally discovered as an inducer of vascular
permeability (Dvorak et al., 1979) and is considered the most potent
growth factor in vessel development. There are several transgenic
Vegf-A mice which all vary in their expression levels. Mice which are
heterozygous null for Vegf-A (Vegf-Aþ /) are embryonically lethal at
E11–12 due to failed vascular development (Carmeliet et al., 1996;
Ferrara et al., 1996) while homozygous null mice are lethal earlier
with severe vascular and hematopoietic defects (Carmeliet et al.,
1996). Interestingly, it has also been observed that mice with
moderate overexpression of Vegf-A are also embryonically lethal at
E12.5–14 due to severe cardiovascular defects (Miquerol et al., 2000).
Signiﬁcantly, this demonstrates the critical role of well-regulated
Table 3
Genotypes of offspring from heterozygous Tie2Cre and heterozygous Pik3caH1047R crosses.
Embryonic age Genotype N Total N Resorbed embryosa N Probability (χ2 test)
Tie2Creþ:Pik3caH1047R Tie2Creþ:Pik3caWT Tie2Cre:Pik3caH1047R Tie2Cre:Pik3caWT
8.5 2 3 5 4 14 0 NSb
9.5 18 11 25 11 65 2 NS
10.5 5c 4 4 5 18 3 NS
11.5 0 1 3 2 6 2 NS
Live born 0 29 35 30 94 – po0.0001
Total 25 48 72 52 197 7
a Resorbed embryos could not be genotyped.
b NS, not signiﬁcant.
c Embryos were severely stunted in growth and clearly not viable.
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Vegf-A signalling during mouse development similar to that which
we have demonstrated is critical for PI3K/Akt signalling.
Our results demonstrate an essential role for ﬁnely-tuned PI3K
activation to control expression of VEGF and other members of the
VEGF signalling pathway. We identiﬁed a greater than 5 fold
increase in VEGF levels in embryos expressing the Pik3caH1047R
mutation. In addition, increased expression of the VEGF receptors
Nrp1, Nrp2 and VEGFR2 was also identiﬁed. Given the requirement
of tightly regulated VEGF signalling in vascular development these
ﬁndings offer a likely explanation for the profound vascular
defects and the embryonic lethality observed in the Pik3caH1047R
mutant embryos. However, the lack of Nrp1 and Nrp2 protein
expression speciﬁcally in the vessels of the mutant embryos
(Fig. 2) suggests that the more global increases in expression of
these genes detected in mRNA extracted from whole embryos
(Fig. 5) may be related to their role in neuronal, neural crest and
somitic development (Schwarz et al., 2009; Schwarz and
Ruhrberg, 2010) that also occurs at this point in development.
Our observation that Pik3caH1047R and Tie2Cre:Pik3caH1047R
mutant embryos had reduced blood cells within the embryo and
yolk sac was unexpected as the PI3K signalling pathway has not
previously been implicated in primitive hematopoesis. At E8.5
VEGFR2 and eosin staining identiﬁed numerous blood islands and
blood cells scattered throughout the yolk sac of both mouse lines,
however, by E9.5 mutant embryos had a dramatic reduction in
blood cells. As Tie2 also drives Cre expression in the primitive
Fig. 6. Targeted expression of the Pik3caH1047R mutation to endothelial cells in the developing embryo leads to delayed development at E9.5 and severe defects by E10.5.
(A) Embryos from the Tie2Creþ /xPik3caH1047R/WT cross targeting expression of the Pik3caH1047R mutation to endothelial cells were dissected at several time points during
development; E9.5 and E10.5. Representative images of the embryos of both genotypes at the two time points are shown. At E9.5, Tie2Cre:Pik3caH1047R mutant embryos were
slightly smaller than control Tie2Cre and Pik3caH1047R embryos which became more evident at E10.5 (inset shows the mutant embryo at the same scale as the control
embryos). Scale bars, 500 μm. (B) Whole-mount endomucin staining (green) was performed on the embryos to assess the vascular system in both Tie2Cre control and
Tie2Cre:Pik3caH1047R mutant embryos (top panel). Arrows indicate organised vessels in the head of the control embryo which are absent in the mutant (middle panel,
indicated by the left Δ). Lack of vessel in the ﬁrst pharyngeal arch in the mutant embryo is also indicated by the right Δ in the middle panel. In the bottom panel, sprouting
vessels into the dorsal region of the embryos are indicated by white arrowheads in the control embryo which are absent in the mutant (indicated by Δ). ACV, anterior
cardinal vein; DA, dorsal aorta; e, eye; ISV, intersomitic vessel; ov, otic vesicle. Scale bars, 100 μm.
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angioblast, future studies would beneﬁt from investigating if this
reduced number of erythrocytes results from a primary role of
PI3K in hemangiogenesis and hematopoesis or if this reduction is
secondary to aberrant blood vessel / blood island development.
Our data suggest that activating mutations in the PIK3CA gene
are not compatible with germline transmission. Indeed, there is
only a single report of germline PIK3CA mutations, in 8 individuals
with Cowden or “Cowden-like” syndrome (Orloff Mohammed
et al., 2013). However, apart from 2 patients both with dual
c.16344A4C and c.1658_1659 delGTinsC changes (that are iden-
tical to the known sequence of the PIK3CA pseudogene found on
human chromosome 22q11.2 (Saal et al., 2005; Tanaka et al.,
2006)), the reported mutations are not within known oncogenic
‘hot spot’ regions in the PIK3CA gene and MutPred software used
to predict the functionality of germline mutations predicts them to
be benign variations (Orloff Mohammed et al., 2013).
Consistent with the lack of germline PIK3CA mutations in
cancer patients, PIK3CA mutations recently reported to be respon-
sible for a variety of segmental overgrowth syndromes, including
CLOVES, hemimegaencephaly and ﬁbroadipose hyperplasia (FH),
are acquired post-zygotically and are not inherited (Lee et al.,
2012; Riviere et al., 2012; Lindhurst et al., 2012; Kurek et al., 2012;
Keppler-Noreuil et al., 2014). Interestingly, individuals with these
overgrowth conditions have been observed to have vascular
malformations including capillary venous and/or lymphatic mal-
formations (Kurek et al., 2012). Patterning defects are also
observed in a large number of these individuals and polydactyly
or syndactyly in the hands and or feet is seen in most cases
(Kurek et al., 2012; Keppler-Noreuil et al., 2014). Such vascular
and patterning defects are consistent with the phenotypes
observed here when Pik3caH1047R is ubiquitously expressed during
embryogenesis.
Fig. 7. Vascular speciﬁcation defects in E9.5 embryos when the Pik3caH1047R mutation is targeted to endothelial cells. Transverse sections through the pharyngeal arch region
of E9.5 Tie2Cre control and Tie2Cre:Pik3caH1047R embryos were stained for endomucin (green), DAPI (blue) and either Nrp1 (red, A) or Nrp2 (red, B). Higher magniﬁcation of
the DA lacking Nrp1 staining is shown (inset, A) while the ACV lacking Nrp2 staining is also shown (inset, B). Anatomical features are indicated with the following
abbreviations-ACV, anterior cardinal vein; DA, dorsal aorta; nt, neural tube; PAA, pharyngeal arch artery. Scale bars 100 mm.
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Our results add to the growing body of work highlighting the
essential role of the PI3K pathway in vascular development and
demonstrate an essential requirement for tight regulatory control
over PI3K activity during embryonic development. The lethality
associated with heterozygous expression of the Pik3caH1047R muta-
tion during development likely explains the lack of inherited
germline PIK3CA mutations in humans.
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